Acute coronary artery stent thrombosis following rapid renewal of functional platelets: Implications for intensified antiplatelet therapy

Christian Schulz; Albert Schömig; Adnan Kastrati

doi:10.1160/TH06-04-0207

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 96(03): 384-386
DOI: 10.1160/TH06-04-0207

Case Report

Schattauer GmbH

Acute coronary artery stent thrombosis following rapid renewal of functional platelets: Implications for intensified antiplatelet therapy

Autor*innen

Christian Schulz

¹Deutsches Herzzentrum, Technische Universität München, München, Germany
Albert Schömig

¹Deutsches Herzzentrum, Technische Universität München, München, Germany
Adnan Kastrati

¹Deutsches Herzzentrum, Technische Universität München, München, Germany

Abstract

Volltext

Referenzen

References
1 Schühlen H, Kastrati A, Dirschinger J. et al. Intracoronary stenting and risk for major adverse events during first month. Circulation 1998; 98: 104-11.
2 Cutlip DE, Baim DS, Ho KK. et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-71.
3 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
4 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
5 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
6 Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
7 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
8 Müller I, Seyfarth M, Rüdiger S. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.
9 von Beckerath N, Taubert D, Pogatsa-Murray G. et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE trial. Circulation 2005; 112: 2946-50.
10 Kastrati A, Mehilli J, Schühlen H. et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-8.
11 Simon BC, Herzum M, Klisch A. et al. Acute severe thrombocytopenia after c7E3 Fab (abciximab) therapy in a patient with unstable angina and stenting of the right coronary artery. Occurence of subacute stent thrombosis and safe readministration of the GPIIb/IIIa inhibitor tirofiban. IntJ Cardiovasc Intervent 2000; 03: 185-8.
12 Elikowski W, Rzezniczak J, Slomczynski M. et al. Profound thrombocytopenia after abciximab administration in acute myocardial infarction and stent thrombosis following thrombocytopenia remission - a case report. Kardiol Pol 2005; 62: 44-7.